PIK3CA and cancer: We evaluated the cytotoxic effects of the currently accepted therapeutic agents (gemcitabine plus cisplatin) and novel targeted compounds (MEK, PI3K and HDAC inhibitors) on the drug sensitivity versus resistance of KRAS mutant and KRAS wild-type cancer cells.